Dolutegravir(DTG, S/GSK1349572) combined with other ARTs is superior to RAL- or EFV-based regimens for treatment of HIV-1 infection: a meta-analysis of randomized controlled trials

BACKGROUND: The first-generation integrase inhibitors (INIs) raltegravir (RAL) and elvitegravir (EVG) have shown efficacy against HIV infection, but they have the limitations of once-more daily dosing and extensive cross-resistance. Dolutegravir (DTG, S/GSK1349572), a second-generation drug that ove...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Junjun, Xu, Xi, Guo, Wenqin, Su, Jinming, Huang, Jiegang, Liang, Bingyu, Chen, Hui, Zang, Ning, Liao, Yanyan, Ye, Li, Liang, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5016965/
https://www.ncbi.nlm.nih.gov/pubmed/27617024
http://dx.doi.org/10.1186/s12981-016-0115-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5016965/
https://www.ncbi.nlm.nih.gov/pubmed/27617024
http://dx.doi.org/10.1186/s12981-016-0115-x

Ejemplares similares